Get a reply from this employer
Your resume and cover letter, tailored to exactly what they’re hiring for.
Immix Biopharma is seeking a Clinical Research Associate II (Cell Therapy) to act as the primary liaison between Investigator sites and Immix, ensuring site conduct per ICH GCP and FDA regulations while supporting the Nexcella oncology program.
The role involves site selection, initiation, monitoring, data verification, IP management, and collaboration with the study team to drive data quality and patient safety.
Our mission is to harness the immune system through innovative cell therapies and other modalities to deliver widely accessible cures. Patients are waiting!
The Clinical Research Associate (CRA) II will be the primary liaison between the Investigator sites and Immix, responsible for overall site conduct and establishing important relationships with key site personnel. The CRA will perform key job functions in accordance with ICH Good Clinical Practice (ICH GCP), FDA regulations, Immix SOPs and work practices while supporting the organizational mission to advance the development of promising oncology therapies and technologies to benefit patients. CRAs are expected to work in a hands-on, highly visible and autonomous role. CRAs must have the ability to be flexible and represent Immix in a positive and professional manner while collaborating across all levels with the clinical teams and Sponsors/vendors.
Immix Biopharma, Inc. is a global leader in AL amyloidosis. AL amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non‑specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi‑center study for relapsed/refractory AL amyloidosis NEXICART‑2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.